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Summary 
Haematopoietic stem cell transplantation (HSCT) is used to treat haematological 
malignancies and bone marrow (BM) failures. For many years BM was the only source of 
haematopoietic stem cells (SCs) for transplantation, but now SCs from mobilised 
peripheral blood (mPB) and cord blood (CB) are increasingly used. Cord blood 
transplantation (CBT) presents several advantages compared to bone marrow 
transplantation (BMT) including a greater tolerance to histocompatibility leukocyte antigen 
(HLA) disparity, a lower risk of graft versus host disease (GvHD) and a preserved graft 
versus leukaemia (GvL) effect. However, GvHD remains a major cause of morbidity and 
mortality after HSCT.  
Cyclosporine A (CsA) and methotrexate (MET) were the standard 
immunosuppressive drugs used as prophylaxis treatment for GvHD in the United Kingdom 
(UK), but over the past twenty years new immunosuppressive drugs were developed in 
order to improve the efficacy and decrease the side effects of CsA and MET, such as 
mycophenolate mofetil (MMF), anti-T lymphocyte globulin (ATG), Campath and Rapamycin 
(RAPA). 
CsA and MMF have been successfully used alone or in combination to prevent 
GvHD. The effects of those two immunosuppressive drugs have been studied on T cells, 
but little is known about their effects on natural killer (NK) cells.  
NK cells provide the beneficial GvL effect without causing GvHD, contributing to 
reduced relapse rates. Moreover, NK cells reconstitute early after CBT providing GvL and 
the first line of defence against infectious organisms. Several studies have shown that NK 
cells are beneficial for clinical outcome.  
To determine the effects of MPA, CsA and the combination of the drugs on 
peripheral blood (PB) and CB NK cells an approach based on flow cytometry and 
quantitative real time PCR was used. 
MPA and MPA+CsA induced cell death of CB NK cells, but not of PB NK cells. The 
immunosuppressants did not have a significant effect on the expression of the activation 
markers CD69 and NKp44 by NK cells, but significantly reduced CB NK cell proliferation. 
MPA reduced perforin production by PB NK cells, while CsA and MPA+CsA drastically 
decreased PB and CB NK cell degranulation. 
This study showed that all drugs tested had significant effects on NK cells that 
could jeopardise their beneficial effects after HSCT. We demonstrated that CB NK cells 
were more sensitive to the drugs than PB NK cells. However, this difference of sensibility 
could not be explained by significant differences in the expression of the drug targets, 
IMPDH1, IMPDH2 and NFATc between PB and CB NK cells. These data suggest that the 
immunosuppressive drug dosage could be adjusted for CBT or maybe alternatives to MMF 
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and CsA could be used in order to prevent GvHD, without jeopardising NK cell 
functionality. 
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Resumo 
O transplante de células estaminais hematopoiéticas é utlizado para tratar doenças 
hematológicas malignas e falhas da medula óssea. Durante muitos anos a medula óssea 
foi a única fonte de células estaminais hematopoiéticas utilizadas em transplantes, mas 
agora células estaminais mobilizadas do sangue periférico e células estaminais do cordão 
umbilical são cada vez mais utilizadas. Algumas das vantagens do transplante do cordão 
umbilical em comparação com o transplante de medula óssea incluem uma maior 
tolerância a incompatibilidades do antígeno leucocitário humano, uma menor incidência 
da doença do transplante contra o hospedeiro e obtenção do efeito imunológico do 
enxerto contra leucemia. No entanto, a doença do transplante contra o hospedeiro 
continua sendo a maior causa de morbilidade e mortalidade após o transplante de células 
estaminais hematopoiéticas. 
Cisclosporina A e metotrexato eram os fármacos imunossupressores padrão 
utilizados no tratamento profilático da doença do enxerto contra o hospedeiro no Reino 
Unido, mas ao longo dos últimos vinte anos novos fármacos imunossupressores têm sido 
desenvolvidos com o objectivo de melhorar a eficácia e minimizar os efeitos secundários 
desses fármacos. Alguns exemplos dos fármacos de nova geração desenvolvidos são o 
micofenolato de mofetila, globulina anti-linfócito T, campath e rapamicina.   
Ciclosporina A e micofenolato de mofetila têm sido eficazmente utilizados 
individualmente ou em combinação para prevenir a doença do enxerto contra o 
hospedeiro. Os efeitos desses dois fármacos imunossupressores têm sido estudados em 
linfócitos T mas sabe-se muito pouco sobre os seus efeitos nas células natural killer (NK).  
As células NK exercem o efeito imunológico benéfico do enxerto contra leucemia 
sem provocar a doença do enxerto contra o hospedeiro, contribuindo assim para a 
redução da reincidência da doença. Para além do mais, as células NK reconstituem num 
curto período de tempo após o transplante do cordão umbilical, proporcionando não só a 
primeira linha de defesa contra agentes infecciosos, mas também o efeito imunológico do 
enxerto contra leucemia. Vários estudos têm demostrado que as células NK têm um efeito 
benéfico no resultado clínico dos pacientes. 
Para determinar os efeitos do ácido micofenólico, ciclosporina A e da combinação 
dos fármacos nas células NK do sangue periférico e do cordão umbilical, foi utilizada uma 
metodologia baseada em citometria de fluxo e reações quantitativa de polimerase em 
cadeia detectada em tempo real.  
O micofenolato de mofetil e a sua combinação com ciclosporina A induziu a morte 
celular das células NK do cordão umbilical, mas não das células NK do sangue periférico. 
Os imunossupressores não tiveram um efeito significativo na expressão dos marcadores 
de ativação CD69 e NKp44 pelas células NK, mas reduziram significativamente a 
proliferação das células NK do cordão umbilical. O micofenolato de mofetila também 
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XXII 
reduziu a produção de perforina pelas células NK do sangue periférico, enquanto que a 
ciclosporina A e a combinação dos fármacos reduziu drasticamente a degranulação das 
células NK de ambas as fontes. 
Este estudo mostrou que todos os fármacos testados apresentam efeitos 
significativos nas células NK que podem prejudicar o seu efeito benéfico após o 
transplante de células estaminais hematopoiéticas. Demonstramos ainda que as células 
NK do cordão umbilical são mais susceptíveis aos imunossupressores do que as células 
NK do sangue periférico. No entanto, esta diferença de susceptibilidade não pode ser 
explicada com base em diferenças significativas dos alvos moleculares dos fármacos, 
como IMPDH1, IMPDH2 e NFATc, entre células NK do sangue periférico e do cordão 
umbilical. Estes resultados sugerem que a dosagem dos fármacos imunossupressores 
pode ser ajustada para o transplante do cordão umbilical ou então alternativas ao 
micofenolato de mofetila e ciclosporina A devem ser pensadas de forma a prevenir a 
doença do enxerto contra o hospedeiro sem prejudicar a funcionalidade das células NK. 
Introduction 
 1 
Introduction 
1. Human Natural Killer Cells 
Natural killer (NK) cells are large, granular, bone marrow (BM)-derived cells 
that constitute approximately 10-15% of human peripheral blood lymphocytes 
(PBL), however, this proportion can vary with age [1]. They are an essential 
element of the innate immune system, mediating early defence through cellular 
cytotoxicity against infectious organisms or transformed cells without previous 
sensitisation and through production of a wide variety of chemokines and 
cytokines that influence other cellular compartments of the immune system [1, 
2]. 
NK cell receptors are germline-encoded, but unlike B and T cells, they do not 
undergo somatic recombination [1]. It is the balance of signals from activating 
and inhibitory receptors that determines the outcome of NK cell function [3]. 
Every healthy cell expresses major histocompatibility complex (MHC) class I 
molecules that are recognised by specific inhibitory NK cell receptors. This 
interaction allows NK cells to recognise self from non-self preventing auto-
immunity [3, 4]. Infections and tumour transformation lead to a loss of MHC class 
I expression, triggering NK cell activation, as proposed by the “missing-self” 
hypothesis [5].  
NK cells use several mechanisms to kill their cellular targets, including 
calcium (Ca
2+
) dependent exocytosis of perforin and granzyme cytotoxic proteins, 
Fas/FasL mediated apoptosis, membrane bound or secreted cytokines such as 
tumor necrosis factor- (TNF-[6] and antibody dependent cellular cytotoxicity 
(ADCC) [7].  
Besides target recognition, NK cell effector functions can be triggered by 
cytokine stimulation. Infected or activated dendritic cells (DCs) and macrophages 
produce cytokines such as interferon- (IFN-, interleukin (IL)-12, IL-15 and IL-
18 that stimulate NK cells to produce other cytokines including IFN-and TNF-. 
In addition, several chemokines are also secreted [8, 9]Regulatory pathways that 
control NK cell cytokine production are particularly relevant during early phases 
of inflammatory response [8]. 
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1.1. NK Cell Subsets 
Two distinct NK cell subsets in humans can be characterised according to 
their relative expression of CD56 and to major functional differences: cytolytic 
activity, cytokine production and homing capabilities [10, 11].  
The majority (90%) of human NK cells are CD56
dim
, meaning they have low 
surface density expression of CD56. This population is primarily CD16
+
, killer cell 
immunoglobulin-like receptor (KIR)
+
 and display low cytokine production, but 
potent cytotoxicity. CD56
dim
 cells predominate in peripheral blood (PB) and 
inflamed tissues. In contrast, a minority of human NK cells (10%) are CD56
bright
, 
have low or absent CD16 and KIR expression, have low cytolytic activity, but 
release high levels of cytokines. They predominate in lymph nodes (LN) (Figure 1) 
[10, 11]. 
(a) (b)
 
Figure 1. Schematic of human NK cell subsets exhibiting differential receptor profiles and 
functions. (a) CD56
bright
 NK cells produce high levels of cytokines and exhibit high 
lymphokine-activated killer (LAK) activity but low natural cytotoxicity and antibody-
dependent cellular activity. (b) By contrast, CD56
dim
 NK cells produce low levels of 
cytokines but are potent mediators of ADCC, LAK and natural cytotoxicity. CD56
dim
 have a 
more granular morphology and express high-level of KIRs when compared with CD56
bright
 
cells. However, CD56
bright
 NK cells display a higher expression of CD94/NKG2A and L-
selectin. From Cooper et al., 2001 [11].  
1.2. NK Cell Development 
As all cells of the haematopoietic system human NK cells derive from CD34
+
 
haematopoietic stem cells (HSCs). It is believed that the BM microenvironment is 
needed for NK cell full maturation [12]. BM ablation studies in mice provided the 
first evidence of its importance for NK cell development in vivo [13, 14]. 
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Mature NK cells do not express CD34 and are CD3
-
CD56
+
 [15] although 
additional antigens are required to distinguish between functionally mature NK 
cells and immature intermediates.  
Human NK cell development can be divided into different stages. Briefly, NK 
cell progenitors in the BM interact with stromal growth factors and generate an 
intermediate NK cell precursor (CD34
+
IL-2/IL-15R+CD56-). Becoming responsive 
to IL-15, this precursor is able to develop into a functional CD56
+
 NK cell [12].  
Freud et al. identified and characterised 4 distinct stages of NK cell 
differentiation, using CD34
+
 haematopoietic progenitor cells (HPCs) from 
secondary lymphoid tissues (SLT), as follows: stage 1 CD34(+)CD117(-)CD94(-); 
stage 2, CD34(+)CD117(+)-CD94(-); stage 3, CD34(-)CD117(+)CD94(-); and stage 
4, CD34(-)CD117(+/-)CD94(+). CD56 expression progressively increases as NK 
cell differentiation progresses from one stage to another to reach a level similar 
to PB CD56
bright
 NK cells at stage 4 of differentiation. They also showed that the 
commitment to NK cell lineage occurs at stage 3, prior to NK cell functional 
maturity, which occurs from stage 4 [16].  
When generated in vitro, NK cells were CD56
bright
 not CD56
dim
. This finding 
can be explained by the requirement of other soluble factors or cell-cell 
interactions that are not present in vitro. Parrish-Novak et al. showed that IL-21 in 
combination with IL-15 is involved in the development of CD56
+
CD16
+
 NK cells 
from BM HPCs in vitro [17]. However, it is not clear whether these cells are 
phenotypically and functionally similar to PB CD56
dim
 NK cells. Several studies 
support the hypothesis that CD56
dim
 population might represent the terminally 
differentiated stage of NK cell development [16, 18, 19]. 
1.3. NK Cell Recognition and NK Cell Receptors 
Similarly to T cells, human NK cell recognition occurs through cell surface 
receptors. While T cells possess T cell receptors (TCRs), NK cells display an array 
of molecules; e.g. immunoglobulin-like and C-type lectin receptors. 
Normal and healthy cells expressing MHC class I molecules will be 
specifically recognised by inhibitory NK cell receptors that will prevent NK cell 
activation while the interaction with transformed or non-self cells that have lost or 
exhibit altered MHC class I molecules expression will result in NK cell activation. 
Even though this is the main mechanism of NK cell recognition, MHC class I 
molecules are not always required for protection from NK cell lysis, and inhibition 
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by MHC class I molecules may not always be sufficient to prevent NK cell 
mediated cytotoxicity. For example class I-deficient non-haematopoietic tissues, 
such as skin grafts, cannot be rejected by NK cells, whereas NK cells are still able 
to kill some virus-infected cells that maintain the expression of MHC class I 
molecules [20, 21]. 
Three major superfamilies of NK cell receptors (NKRs) have been described 
in humans: the KIR superfamily, the C-type lectin superfamily and the natural 
cytotoxicity receptor (NCRs) family.  
KIRs specifically recognise classical human leucocyte antigens (HLA-A, -B and 
–C), but also non-classical molecules such as HLA-G. They appear to play a role in 
the induction of NK cell tolerance to self, allowing the development of NK cells 
that are responsive against target cells, but tolerant to self MHC positive cells in a 
process named “licensing” [22].  
C-type lectin receptors are selectively expressed by NK cells and cytotoxic T 
lymphocytes. These receptors react to the level of non-classical MHC class I 
molecules expressed on the surface of potential target cells. CD69 is a C-type 
lectin receptor, which appears to be the earliest molecule to be expressed on the 
surface of T and NK cells during activation [23]. Another example of C-type lectin 
receptor is the CD94/NKG2 heterodimer [24, 25]. NKG2D is the best-
characterised NK cell activating receptor and is also a C-type lectin surface 
receptor distantly related to the NKG2 family, but expressed as a homodimer 
[26]. 
NK cell related protein (NKp) 46, NKp44 and NKp30 are part of the NCR 
family, which play an important role in the recognition of tumour cells. NKp46 
and NKp30 are constitutively expressed by all PB NK cells and are not expressed 
by other immune cells [27, 28]. NKp44 is not expressed by resting NK cells, but is 
upregulated after activation such as IL-2 stimulation and may be important for the 
cytotoxicity of these cells [29]. NKp44 is also expressed by a proportion of  T 
cells and NK22 cells [30]. NCR do not recognise MHC molecules, but viral 
hemagglutinins, heparin sulfate proteoglycan and nuclear factors released from 
tumour cells [31-33].  
CD16 is a receptor expressed on NK cells that does not fit into any of the 
categories described above. This receptor is a member of the Fc receptor family, 
which recognises IgG. In contrast to receptors previously described that mediate 
natural cytotoxicity, CD16 mediates ADCC. The engagement of CD16 with its 
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ligand is capable of triggering by itself cytotoxicity and cytokine release of resting 
NK cells [34].  
Other receptors have been implicated in the process of triggering NK cell-
mediated cytotoxicity including natural killer receptor 2B4 (CD244) [35], CD2 
(T11) [36], CD40 ligand [37], DNAX accessory molecule-1 (DNAM-1, also known as 
CD226) [38], killer cell lectin-like receptor subfamily G member 1 (KLRG1) [39], 
lymphocyte function-associated antigen-1 (LFA-1, also known as CD11a) [40], 
NKp80 [41] and paired Ig-like receptor (PILR) [42]. Most of these receptors require 
synergies with other receptors to activate cytotoxicity and cytokine production by 
resting NK cells. For activated NK cells, coactivation of specific pairs of receptors 
enhances NK cell cytotoxicity and cytokine production [34].  
2. CB NK Cells 
Phenotypic and functional similarities and differences between PB and cord 
blood (CB) NK cells have been reported [43]. Some investigators have reported CB 
NK cells as mature [44], while others have reported them as immature [45, 46].  
NK cells are more abundant in CB than in PB, constituting up to 33% of CB 
lymphocytes [47]. The two major populations of NK cells, CD56
dim
 and CD56
bright
 
exist in similar proportions in CB and PB [44, 48], however, Luevano et al. 
reported a slightly higher percentage of CD56
bright
 cells in CB [46]. 
To assess the functionality of NK cells, the expression of activating and 
inhibitory receptors by CB and PB NK cells have been studied, the data from three 
different studies are summarised in Table 1. 
Table 1. Comparative expression of inhibitory and activating receptors on CB and PB NK 
cells.  higher expression on CB,  similar expression on CB,  lower expression on CB, 
compared to PB, --- not studied. 
 Inhibitory Receptors Activating Receptors 
 CD158a CD158b NKG2A NKG2D NKp46 
Luevano et al. 2012 [46] dimbright dimbright dimbrightdimbright dimbright
Wang et al. 2007 [49]     
Dalle et al. 2005 [44]   --- --- --- 
 
The acquisition of lytic activity is associated with NK cell maturity. Some 
studies suggested that the expression of cytotoxic molecules such as FasL, 
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perforin and granzyme B do not differ between CB and PB NK cells, while other 
studies showed a lower percentage of CB NK cells expressing these molecules 
and others even showed an increase in the perforin and granzyme B producing-CB 
NK cells (Table 2). Despite controversies in the expression of cytotoxicity-related 
molecules by CB NK cells (Table 2), it seems consensual that resting CB NK cells 
are less cytotoxic than resting PB NK cells against K562 cells [44, 46, 48]. A lower 
expression of adhesion molecules and a higher expression of inhibitory receptors 
might account for the reduced CB NK cell cytotoxicity [46, 48, 49]. Nevertheless, 
CB NK cell cytotoxicity is enhanced after IL-2, IL-12 or IL-15 stimulation [44-46]. 
Table 2. Comparative expression of cytotoxicity-related molecules in CB and PB NK cells. 
 higher expression on CB,  similar expression on CB,  lower expression on CB, 
compared to PB. 
 Fas-L TRAIL Perforin Granzyme B 
Luevano et al. 2012 [46] dimbright dimbright dimbright dimbright 
Wang et al. 2007 [49]     
Dalle et al. 2005 [44]     
 
Several studies have compared IFN- production by CB and PB NK cells 
stimulated with phorbol 12-myristate 13-acetate (PMA) and an ionophore. Wang et 
al. and Dalle et al. showed no differences in the expression of IFN- by NK cells 
from CB and PB [44, 49], but Luevano et al. studied both NK cell subsets, showing 
a lower percentage of CD56
dim
 subset expressing IFN- and a trend for the 
CD56
bright
 subset [46].  
In addition to the characterisation of the phenotypic and functional 
properties, the questions of the development and homing properties of CB NK 
cells compared to PB NK cells were recently addressed by Luevano et al. [46]. This 
study showed that even though the majority of CB NK cells are in the stage 4 
according to the developmental stages defined by Freud et al. [16], their 
maturation seems to be incomplete. Moreover, CB NK cells seem to have a great 
potential to migrate to the BM, but not to LN as observed for PB NK cells [46]. 
3. Haematopoietic Stem Cell Transplantation 
Haematopoietic stem cell transplantation (HSCT) is a common treatment of 
malignant (e.g. leukaemia and lymphoma) and non-malignant (e.g. thalassemia 
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and inborn errors of metabolism) disorders [50]. The number of HSCT performed 
worldwide has been increasing and the overall survival has improved due to 
advances in techniques, such as non-myeloablative conditioning, cord blood 
transplantation (CBT) and donor lymphocyte infusion allowing a higher number of 
people who are in need of HSCT to benefit from this treatment [51, 52]. 
3.1. Type of Donor and Source of Stem Cells 
75% of patients in need of HSCT do not have an HLA-matched sibling, thus 
the recruitment of alternative donors such as matched unrelated volunteers and 
partially mismatched donors or the use of unrelated CB are required. For many 
years, BM was the only source of HSCs. Today, other sources of HSCs are used 
including CB units, granulocyte-colony-stimulating factor (G-CSF)-mobilised PB 
(mPB) HSCs/HPCs [53].  
PB does not naturally contain a high percentage of HSCs/HPCs, but they can 
be mobilised from BM with G-CSF and/or AMD3100 (Plerixafor). Thereby, it is 
possible to obtain a high percentage of HSCs/HPCs in a volume of blood up to 20 
L, with fewer side-effects for the donor. Unfortunately, mPB also contains a high 
percentage of T cells, increasing the incidence of GvHD [54]. 
CB is increasingly used as a source of SCs for transplantation mainly when 
suitable donors are not found. CB is rich in HSCs, but limited in volume. Despite 
the slow immune reconstitution and the increased risk of infections, CBT presents 
several advantages including off-the-shelf availability, a greater tolerance to HLA 
disparity and a lower risk of GvHD [55, 56]. For children, CB is now often chosen 
over mPB and BM [57].  
3.2. Preparative Regimens 
Prior to HSCT, a preparative regimen is required in order to eradicate cancer 
cells and to ablate the immune system of the patient preventing graft rejection 
[58].  
Myeloablative regimens such as total-body irradiation (TBI) are very effective 
in eliminating tumour cells, consequently reducing relapse rates. The 
effectiveness of these regimens is due to the independence of blood supply and 
local shielding of organs. Thus, TBI can reach sites that chemotherapy cannot, 
however, these regimens are associated with high toxicity [59]. To reduce 
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toxicity, fractionated dose of TBI combined with chemotherapeutic agent has 
been used [58].   
Lately, an innovative approach combined reduced intensity conditioning 
(RIC) with alloreaction in the graft-versus-host (GvH) direction. The RIC is mainly 
immunosuppressive, while the GvH alloreactivity results in recognition and 
elimination of malignant cells. This is known as the graft-versus-leukaemia (GvL) 
effect. Older recipients and patients with co-morbidities are the ones who benefit 
the most of this preparative regimen, otherwise they would not be able to 
undergo HSCT [60]. 
Radiation-free regimens, including chemotherapeutic drugs as busulfan and 
cyclophosphamide are also available [61].   
3.3. GvL versus GvHD 
T cells contribute to a rapid engraftment and successful development of 
immune tolerance and immune reconstitution. Moreover, they are GvL effectors. 
Unfortunately, alloreactive T cells also cause GvHD. Hence, an 
immunosuppressive regimen is given after HSCT to suppress the immune system 
of the patient, in particular T cells, to prevent GvHD [62]. 
GvHD is a major cause of morbidity and mortality after HSCT and the global 
immunosuppression needed to prevent or treat it underlie the major reasons for 
transplant failures: infection and neoplastic relapse [63].  
In turn, NK cells play a central role after HSCT providing GvL effect without 
causing GvHD [64]. Several studies have shown an association between circulating 
NK cells and a reduced risk of relapse, infections and mortality after HSCT [65, 
66]. 
4. Immunosuppressive Drugs 
Immunosuppressive drugs have been used to prevent the 
activation/proliferation of T cells post-transplantation, essential for the immune 
response that leads to undesirable GvHD.  
In the United Kingdom, the standard prophylaxis treatment against GvHD 
includes cyclosporine A (CsA) and methotrexate (MET). However, a new 
generation of immunosuppressive drugs has been developed over the past two 
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decades to improve the efficacy of CsA and MET with minimal side effects. These 
drugs include mycophenolate mofetil (MMF), anti-T lymphocyte globulin (ATG), 
Campath, tacrolimus and Rapamycin (RAPA) [62, 67-70]. 
Different immunosuppressive agents have diverse mechanisms of action, 
such as blocking cell cycle progression (e.g. RAPA and MMF), blocking cytokine 
production through calcineurin inhibition (e.g. CsA and tacrolimus) or killing the 
cells that express its cellular target (e.g. Campath and ATG).  
4.1. Mycophenolate Mofetil 
MMF (CellCept®) is an orally bioavailable prodrug of mycophenolic acid 
(MPA), a fermentation product of several species of Penicillium [71-73]. MMF is 
the 2-morpholinoethyl ester of MPA [74]. It is quickly hydrolysed by esterases 
both in vivo, and in human peripheral blood mononuclear cells (PBMCs) cultures 
in vitro. 
MMF has a bioavailability of around 94% and its metabolisation is primary 
hepatic [74, 75]. The half-life of the drug is of approximately 17 hours and its 
metabolites are excreted in the urine and in the bile [74].  
In addition to its well-established transplant uses, MMF is also used for other 
diseases such as for the treatment of autoimmune diseases [76-79].  
4.1.1. Mechanism of Action 
MPA is a non-competitive and reversible inhibitor of inosine-5’-
monophosphate dehydrogenase (IMPDH), a rate-limiting enzyme that catalyses 
the conversion of inosine monophosphate (IMP) into guanosine monophosphate 
(GMP) in the de novo pathway of purine biosynthesis (Figure 2). IMPDH inhibition 
decreases the guanine nucleotide pools and consequently blocks the de novo 
deoxyribonucleic acid (DNA) synthesis [72, 73].  
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Figure 2. De novo and salvage pathways of purine biosynthesis. MPA inhibits IMPDH that 
catalyses the conversion of inosine monophosphate (IMP) into guanosine monophosphate 
(GMP). AMP, adenosine monophosphate; ATP, adenosine triphosphate; dADP, 
deoxyadenosine diphosphate; dATP, deoxyadenosine triphosphate; GTP, guanosine 
triphosphate; GMP, guanosine monophosphate; dGDP, deoxyguanosine diphosphate; 
dGTP, deoxyguanosine triphosphate; DNA, deoxyribonucleic acid; RNA ribonucleic acid. 
Adapted from Allison et al. 2005. 
4.1.2. Effects on B and T Lymphocytes 
There are two IMPDH isoforms: IMPDH1 and IMPDH2. While most of the cells 
express IMPDH1, IMPDH2 is almost exclusively expressed by B and T 
lymphocytes. Since MMF is 5 times more active on IMPDH2, it selectively affects 
the proliferation of activated lymphocytes, which is almost entirely dependent on 
the de novo pathway for purine synthesis [80]. 
Several papers have reported MMF/MPA as an inductor of apoptosis in T 
lymphocytes [81-83]. Human T lymphocytic and monocytic cell lines treated with 
MPA showed an increase in apoptotic cells [84]. Moreover, MMF supresses 
cytotoxic T lymphocyte generation [72].  
Eugui et al. described MPA as an inhibitor of antibodies formation by 
activated B cells [71]. 
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4.1.3. Effects on NK Cells 
Recently, Ohata et al. described MPA as an inhibitor of PB NK cell 
proliferation and cytotoxic function. They suggested that the inclusion of MMF in 
the GvHD prophylaxis treatment may not be advantageous [85]. 
Eissens et al. demonstrated that MPA impairs human PB NK cell cytotoxicity 
due to differential effects on NK cell phenotype. The most important effects 
observed were the inhibition of the proliferation of the CD56
bright
CD16
+/-
 subset 
and the inhibition of IFN- production, suggesting that MPA might have a negative 
effect on NK cell mediated GvL responses in vivo after HSCT [86].  
4.1.4. Effects on Dendritic Cells 
DCs are the most important antigen presenting cells, especially during 
primary immune responses. Mehling et al. showed that MMF impairs the 
maturation and function of murine dendritic cells due to the downregulation of 
co-stimulatory molecules, CD40 and CD86, required for the maturation process. 
Similarly, studies on human monocyte-derived DCs showed that MPA suppresses 
their maturation and allostimulatory functions, highlighting a beneficial role for 
transplantation through tolerance induction [87]. 
4.1.5. Effects on Adhesion Molecules 
An in vitro study conducted by Blaheta et al. showed that MMF suppresses in 
a dose-dependent manner the glycosylation and expression of several adhesion 
molecules such as vascular cell adhesion protein (VCAM)-1, E-selectin and P-
selectin on T lymphocytes [88]. Furthermore, it was shown that MMF impairs T 
cell transendothelial migration [88]. In vivo, MMF decreased leucocytic infiltration 
into rat kidney allografts, reducing the incidence of acute rejection [89]. 
4.2. Cyclosporine A  
The cyclic oligopeptide, CsA, was primarily described as derived from the 
fungus Tolypocladium inflatum, but several other microorganisms produce it. 
CsA presents a variety of biological activities, including immunosuppressive, anti-
inflammatory, antifungal and antiparasitic properties [90].  
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Borel et al. were the first to show in 1976 that CsA delays the rejection of 
skin transplants and prevents/treats GvHD in mice [91]. 
Since approved for clinical use as immunosuppressant in 1983, CsA has 
been used in preventing allograft rejection and treating certain autoimmune 
diseases [90].  
4.2.1. Mechanism of Action 
Within the cell, CsA binds to cyclophilin and the complex CsA-cyclophilin 
inhibits calcineurin, a Ca
2+
-dependent serine threonine phosphatase. This 
consequently inhibits the nuclear factor of activated T cells (NFAT) 
dephosphorylation, preventing its translocation into the nucleus. The repression 
of NFAT translocation into the nucleus prevents the transcription of early genes, 
such as IL-2, IL-4, IFN-, TNF, but also FasL and CD40L. Thus, CsA exerts its main 
immunosuppressive effect by inhibiting T cell activation [92]. 
4.2.2. Pharmacokinetic 
CsA pharmacokinetic is highly variable in humans according to the type of 
organ transplanted, the co-administration with other drugs that can interact with 
CsA, the disease state and age of the patient. Its metabolisation occurs in the 
liver and the half-life of the drug is estimated as being between 6.4-8.7 hours 
[92]. 
4.2.3. Toxic Effects 
In addition to its immunologic effects, CsA presents several side effects, 
partly due to calcineurin inhibition in non-lymphatic tissues. Among the most 
prominent side effects are nephrotoxicity and hypertension [92]. However, co-
administration of CsA with other immunosuppressive drugs has shown a 
beneficial synergistic effect with a decrease of its toxic effects [90]. 
4.2.4. Effects on Lymphocytes and other Cell Types  
In 1976, Borel and colleagues [91] thought that CsA was specific of 
lymphocytes, but over the years CsA was shown to have effects on a wide range 
Introduction 
 13 
of cells. In Table 3 are summarised several studies reporting the effects of CsA on 
various cell types. 
Table 3. Summary of studies reporting the effects of CsA on T cells, NK cells and other 
cell types. inhibition; induction;  no difference --- not applicable/not studied; AICD 
activation-induced cell death. 
 
T lymphocytes / 
cytotoxic T 
lymphocytes 
NK cells 
B cells / 
B cell 
line 
Mast 
cells 
Basophils 
Degranulation [93] --- --- [94] [94, 95]
Proliferation [91]
[85, 96]; 
(trend) [86]
--- --- --- 
Cytolytic 
function 
[93]
[96]; [97]; 
[85, 86];  
--- --- --- 
Cytokine 
production 
IFNandTNF
TGF-
IFN-
IFN- 
--- --- --- 
Apoptosis [99]; [100] [96] [100] --- --- 
AICD [101, 102] --- [103] --- --- 
5. Aim 
MMF and CsA have been successfully used worldwide alone or in 
combination for GvHD prophylaxis [104-106]. Although the effects of these 
immunosuppressive drugs have been extensively studied in T cells, little is known 
about their effects on NK cells.  
The aim of the present in vitro study was to gain a better understanding of 
the effects of MPA and/or CsA on PB and CB NK cell phenotype and function. This 
study intended to determine if CB NK cells are more sensitive to the 
immunosuppressants tested than PB NK cells. NK cells have been described as 
effectors of the GvL effect without causing GvHD. Thus, a fully functional NK cell 
population after HSCT is important to obtain a more favourable outcome. Hence 
we intended to identify the immunosuppressive regimen that preserves better NK 
cell functionality.  
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Materials and Methods 
6. Collection of Blood Samples 
PB samples from healthy volunteers were collected in sterile heparinised 
tubes. CB samples were obtained from the Anthony Nolan Cord Blood Bank, 
Nottingham, United Kingdom. Samples were collected, using routine banking 
procedures, into a CB donation bag containing a Citrate-Phosphate-Dextrose 
anticoagulant buffer. Only fresh CB units (up to 48h after collection) were used. 
All samples were collected under written informed consent. 
7. Cell Isolation 
7.1. Peripheral Blood Mononuclear Cell Isolation 
The blood was diluted 1:1 in phosphate buffered saline (PBS) 1X (Lonza, 
Basel). Lympholyte-H® (Cederlane, Gateshead) density gradient was used to 
isolate PBMCs. Cells were washed and counted using trypan blue® (Sigma-Aldrich, 
Dorset) to assess cell viability. Thereafter, cells were either cultured in RPMI-1640 
(Lonza) supplemented with 10% foetal bovine serum (FBS) (Lonza), 1% penicillin-
streptomycin™ (Pen-Strep) (Lonza) and 0.1% -mercaptoethanol (Gibco Invitrogen, 
Paisley) or resuspended in PBS 1X supplemented with 0.5% bovine serum albumin 
(BSA) and 2 mM EDTA (Gibco Invitrogen) for NK cell isolation. 
7.2. Cord Blood Mononuclear Cell isolation 
The blood was diluted 1:1 in RPMI-1640 supplemented with 10% FBS, 1% 
Pen-Strep, 33% trisodium citrate® (AnalaR, Poole) and 0.05 µM -mercaptoethanol 
and allowed to equilibrate at room temperature for 45 minutes. Ficoll-Paque™ Plus 
(GE Healthcare, Chalfont St Giles) density gradient was used to isolate CB 
mononuclear cells (CBMCs). CBMCs were treated with lysing buffer 1X (BD 
Pharmingen, Oxford) at room temperature for 2 minutes to lyse red blood cells, 
washed and counted with Türk solution (methylene blue and 1% acetic acid (v/v)) 
to discriminate red blood cells and trypan blue to assess cell viability of white 
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blood cells. CBMCs were either cultured in RPMI-1640 supplemented with 10% 
FBS, 1% Pen-Strep and 50 µM -mercaptoethanol or resuspended in PBS 1X 
supplemented with 0.5% BSA and 2 mM EDTA for NK cell isolation. 
7.3. Natural Killer Cell isolation 
CB samples were treated with the human granulocyte depletion cocktail 
(StemCell Technologies, Grenoble) before CBMCs isolation to deplete 
granulocytes that could block the column during the CD3
-
CD56
+
 enrichment step. 
CD3
-
CD56
+
 populations were obtained by negative selection using the NK 
cell isolation kit (Miltenyi Biotec, Bergisch Gladbach) according to the 
manufacturer instructions; however, some modifications were applied to improve 
the quality of isolation. After labelling with the NK cell microbead cocktail, cells 
were washed with 25 mL of buffer rather than 1-2 mL of buffer per 10
7
 cells, 
centrifuged at 300xg for 5 minutes and then resuspended in 5 mL of buffer 
instead of 500 µL (up to 10
8
 cells). The magnetic separation was performed using 
LS columns (Miltenyi Biotec) up to 1x10
9
 total cells per column. The labelled cell 
suspension was applied to the column and washing steps were performed twice 
with 7 mL of PBS 1X supplemented with 0.5% BSA and 2 mM EDTA. The enriched 
NK cell fraction (negative fraction) was centrifuged; cells were resuspended in 
RPMI-1640 and counted with trypan blue. 
8. Cell Culture 
PBMCs and CBMCs were cultured in flat-bottom 96 well plates in RPMI-1640 
supplemented with 10% FBS, 1% Pen-Strep, 50 µM -mercaptoethanol without IL 
stimulation in order to test the effects of immunosuppressants on resting NK 
cells. 
However, after 24 hours of culture, most CB NK cells were dead (Figure 3), 
while PB NK cells could withstand without stimulation for a longer time period.  
For that reason the protocol had to be optimised to address the needs of CB 
NK cells and 1000 IU/mL of IL-2 was added to the cultures. Immunosuppressive 
drugs were added at the beginning of the culture. 
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Figure 3. Comparison between resting PB and resting CB NK cell population at 24h after 
cell isolation. FACS plots from a representative donor showing staining for CD3 and CD56 
of resting PBMCs compared to resting CBMCs in the absence of immunosuppressive drugs 
at 24h after cell isolation. 
PB and CB isolated NK cells were cultured in round-bottom 96 well plates in 
RPMI-1640 supplemented with 10% FBS, 1% Pen-Strep, 50 µM -mercaptoethanol 
and IL-2 at 1000 IU/mL for 5 days. Immunosuppressive drugs were added at day 
5. 
Cells were maintained in an incubator (Sanyo) at 37ºC, in a humidified 
atmosphere with 5% CO
2
. The various concentrations of immunosuppressants 
used in different experiments are listed in Table 4. 
Table 4. List of immunosuppressants and their corresponding concentration used in 
different experiments. 
Immunosuppressants Viability Activation 
Granzyme B and 
perforin production 
CD107a 
degranulation assay 
Proliferation 
assay 
MPA (M) 2.5, 5, 7.5 and 10 5 and 10 
CsA (ng/mL) 5, 50, 500 and 5000 50 and 5000 
MPA (M) 
+ 
CsA (ng/mL) 
2.5+5, 5+50, 7.5+500 
and 10+5000 
5+50 and 10+5000 
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9. Phenotypic Analysis  
The following anti-human monoclonal antibodies were supplied by BD 
Pharmingen: CD3-FITC (HIT3), CD3-PE (HIT3), CD3-PerCP (HIT3), CD16-FITC 
(NKp15), CD56-APC (B159), CD56-PE (B159), CD69-PerCP (L78), CD107a (H4A3), 
granzyme B-FITC (GB11) and perforin-PE (G9). 7-aminoactinomycin D (7-AAD), 
annexin-V-FITC, mouse IgG1 κ isotype control FITC (MOPC-21), mouse IgG2b κ 
isotype control PE (G9) were also supplied by BD Pharmingen. NKp44-APC (P44-8) 
was purchased from Biolegend (London). 
For surface labelling, cells were incubated with antibodies in the dark at 4°C 
for 10 minutes, washed and resuspended in either cold PBS 1X with 2% FBS or 
Annexin-V binding buffer (BD Pharmingen) 1X. 
Annexin-V and 7AAD were used to assess NK cell viability, while CD69 and 
NKp44 were the receptors chosen to study NK cell activation. 
Perforin and granzyme B expression was assessed by intracellular staining 
after cell membrane permeabilisation with the Cytofix/Cytoperm
TM
 kit from BD 
Pharmingen. Briefly, a 10% mouse serum blocking step preceded CD3, CD56 and 
CD16 surface labelling at 4°C for 10 minutes in the dark to avoid nonspecific 
binding. Cells were fixed and permeabilised with Cytofix/Cytoperm
TM
 at 4°C for 
20 minutes in the dark. After a second blocking step, cells were incubated either 
with the target or the isotype control antibodies in the dark at 4°C for 1 hour, 
washed twice with Perm/Wash
TM
 buffer 1X and then resuspended in PBS 1X with 
0.1% FBS.  
Cells were acquired using a FACSCalibur flow cytometer (BD Biosciences) and 
the data were analysed using FlowJo software (Tree Star, Oshland). 
9.1. Gating Strategy 
9.1.1. Effects of Immunosuppressants on NK Cell Viability 
The lymphocyte population and the smaller population representing dying 
cells were gated based on forward and side scatter. Subsequent analyses were 
done on CD3-CD56+ cells. Cell death was determined by the expression of 
annexin-V and 7AAD (Figure 4). 
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Figure 4. Gating strategy used for the viability study of NK cells. The example represents 
the analysis of one PBMCs sample. The same gating strategy was applied to CBMCs 
samples.  
9.1.2. Effects of Immunosuppressants on NK Cell Activation 
The lymphocyte population was gated based on forward and side scatter. 
CD69 and NKp44 mean fluorescence intensity (MFI) was determined on NK cells 
by gating on CD3-CD56+ cells (Figure 5).  
 
Figure 5. Gating strategy used to analyse the expression of activation markers on NK 
cells. The example represents the analysis of one PBMCs sample. The same gating 
strategy was applied to CBMCs samples. 
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10. Proliferation Assay 
Freshly isolated NK cells were resuspended in PBS at 10
6
 cells/mL and 
labelled with 2 M carboxyfluorescein succinimidyl ester (CFSE) using the Cell 
Trace CFSE Cell Proliferation Kit (Molecular Probes, Invitrogen, Carlsbad) for 10 
minutes in the dark at 37°C. Cells were washed twice with cold RPMI 
supplemented with 10% FBS and then cultured in RPMI supplemented with 10% 
FBS, 1% Pen-Strep, 50 µM -mercaptoethanol and IL-2 at 1000 IU/mL in the 
presence or absence of immunosuppressive drugs for 5 days. Fresh media with 
1000 IU/mL of IL-2 was added every 2 days and the cells were split when needed. 
Cells were analysed by flow cytometry at day 2 and day 5.  
11. CD107a Degranulation Assay 
Immunosuppressive drugs were added to IL-2 activated NK cells at day 5 of 
culture. At day 7 of culture NK cells were resuspended in 200 µL of fresh RPMI-
1640 supplemented with 10% FBS, 1% Pen-Strep, 50 µM -mercaptoethanol. The 
cells were stimulated with 100 ng/mL of PMA and 1 µg/mL of ionomycin for 2 
hours at 37°C. 10% blocking mouse serum was added for 10 minutes at room 
temperature, the cells were then stained with CD56, CD3, CD16 and either 
CD107a or the corresponding isotype control antibodies, in PBS supplemented 
with 2% FBS and 2 mM EDTA for 45 minutes at 4°C. The cells were then washed, 
resuspended in PBS containing 2% FBS and 2 mM EDTA, and analysed by flow 
cytometry.  
12. RNA isolation 
RNA was extracted using the RNeasy® Mini Kit (Qiagen, West Sussex) from 
both freshly isolated and IL-2 (1000 IU/mL for five days) activated CB or PB NK 
cells according to the manufacturer’s instructions. RNA concentration and purity 
were determined by measuring the optical density at 260 nm (OD
260
) and the 
OD
260
/OD
280
 ratio using a NanoDrop® ND-1000 spectrophotometer (Labtech, East 
Sussex). 
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13. Reverse Transcription 
cDNA was synthesised from 200 ng of RNA using random primers (Promega, 
Southampton) and the SuperScript® III reverse transcriptase (Invitrogen). The mix 
was incubated for 50 minutes at 42°C and then 15 minutes at 70°C to inactivate 
the enzyme. 
14. Real Time PCR 
Quantitative real time polymerase chain reaction (PCR) was performed using 
a 7500 System SDS instrument (Applied Biosystems, Paisley). The data were 
analysed using the 7500 System SDS Software version 1.4 (Applied Biosystems). 
SYBR Green (Primer Design, Southamptom) was used as a fluorogenic probe. The 
 subunit of the mitochondrial ATP synthase (ATP5B), ubiquitin C (UBC) and 
topoisomerase I (TOP I) (Primer Design) were chosen as internal controls. The 
sequences of the primers used are listed in Table 5. Samples and internal controls 
were run in triplicates at the same time in a single 96-well optical reaction plate 
(ABI PRISM, Applied Biosystems). The comparative threshold cycle (Ct) method 
was used to quantify mRNAs.  
Table 5. Primer Sequences. 
 Forward (3’-5’) Reverse (5’-3’) 
IMPDH1 GCACACTGTGGGCGAT GAGCCACCACCAGTTCA 
IMPDH2 TCTTCAACTGCGGAGAC CTGTAAGCGCCATTGCT 
NFATc GCCGCAGCACCCCTACCAGT TTCTTCCTCCCGATGTCCGTCTCT 
15. Statistical Analysis 
An unpaired, 2-tailed Student t-test was performed using Excel® software 
(Microsoft Excel for MAC 2011, version 14.1.0, Berkshire) to analyse the 
statistical significance. Results are presented as mean ± standard deviation (SD). p 
values < 0.05 were considered statistically significant.  
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Results  
1. Effects of Immunosuppressants on NK Cell Viability 
PBMCs and CBMCs were cultured with 1000 IU/mL of IL-2 with increasing 
concentrations of MPA and/or CsA. Cells were stained with CD3, CD56, annexin-V 
and 7AAD to assess NK cell viability. None of the conditions tested decreased PB 
or CB NK cell viability (Figure 6), however, under these conditions there was a 
high percentage of NK cell death at 24 and 48 hours.  
 
 
Figure 6. Influence of immunosuppressants on the viability of non-isolated NK cells. 
Percentage of NK cell death of IL-2 (1000 IU/mL) stimulated PBMCS (N=5) and CBMCs 
(N=5) at 24 and 48 hours after the addition of MPA (2.5, 5, 7.5 and 10 µM) and/or CsA (5, 
50, 500, 5000 ng/mL).  
As the previous in vitro culture conditions showed not to be ideal for NK cell 
survival, we decided to isolate and activate NK cells, prior to the drug addition in 
order to test the effects of the drugs on NK cell viability. PB and CB NK cells were 
isolated by negative selection and cultured with 1000 IU/mL of IL-2 for five days. 
At day 5 of culture, drugs were added at increasing concentrations. Cells were 
stained at day 6 and 7 of culture with CD56, annexin-V and 7AAD.  
For up to day 6 of culture immunosuppressants did not affect PB or CB NK 
cell viability. Nevertheless, at day 7 of culture, MPA and MPA+CsA, not CsA, 
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increased the percentage of cell death of CB NK cells in a dose dependent manner 
compared to untreated cells. The immunosuppressants did not affect significantly 
PB NK cell viability, but MPA showed a trend towards an increase of cell death 
(Figure 7). 
 
Figure 7. Influence of immunosuppressants on the viability of isolated NK cells. 
Percentage of cell death of isolated PB (N=5) and CB (N=6) NK cells activated with 1000 
IU/mL of IL-2. MPA (2.5, 5, 7.5 and 10 µM) and/or CsA (5, 50, 500, 5000 ng/mL) were 
added at day 5 of culture and the cells were stained at day 6 and 7 of culture with 
annexin-V and 7AAD. p<0.05 for MPA-treated cells compared to untreated cells, 
Δp<0.05 and ΔΔp<0.01 for MPA+CsA treated cells compared to untreated cells. 
These data suggest that the drugs affected only activated NK cells. Besides 
CB NK cells were more sensitive to MPA and MPA+CsA than PB NK cells regarding 
cell viability. 
2. Effects of Immunosuppressants on NK Cell Activation 
CD69 is an early activation marker of NK cells. NKp44 is a natural cytotoxic 
receptor that is absent on freshly isolated lymphocytes, but is progressively 
expressed by all NK cells in vitro after activation such as culture with IL-2. This 
last receptor mediates tumour cell killing [29]. Therefore, we analysed the effects 
of the immunosuppressants on the expression of both activation markers, CD69 
and NKp44. 
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No significant changes were observed in the expression of CD69 or NKp44 
on non-isolated PB or CB NK cells treated with any of the immunosuppressants 
(Figure 8).  
The drugs did not significantly affect the expression of either CD69 or 
NKp44 on isolated and activated NK cells, but some trends were observed. CsA 
showed a trend towards the downregulation of CD69 on PB but not on CB NK 
cells, while all the drugs showed a trend towards the downregulation of NKp44 
expression on both PB and CB NK cells (Figure 9). 
Thus, the immunosuppressants did not significantly affect the expression of 
CD69 and NKp44 when they were added to 5 days IL-2 activated PB or CB NK 
cells.  
 
Figure 8. Influence of immunosuppressants on the expression of activation markers by 
non-isolated NK cells. MFI of CD69 and NKp44 activation markers on IL-2 (1000 IU/mL) 
stimulated PBMCS (N=5) and CBMCs (N=5) gated on NK cells at 24 and 48 hours after the 
addition of MPA (2.5, 5, 7.5 and 10 µM) and/or CsA (5, 50, 500, 5000 ng/mL). 
Results 
26 
 
Figure 9. Influence of immunosuppressants on the expression of activation markers by 
isolated NK cells. MFI of CD69 and NKp44 activation markers on IL-2 (1000 IU/mL) 
activated PB (N=5) and CB (N=6) NK cells at day 7 of culture. MPA (2.5, 5, 7.5 and 10 µM) 
and/or CsA (5, 50, 500, 5000 ng/mL) were added at day 5 of culture. 
3. Effects of Immunosuppressants on NK Cell Proliferation 
To study the effects of MPA, CsA and MPA+CsA on NK cell proliferation, 
freshly isolated PB or CB NK cells were labelled with CFSE and cultured up to 5 
days with 1000 IU/mL of IL-2 in the presence or absence of increasing 
concentration of MPA and/or CsA. The CFSE levels were determined by flow 
cytometry at day 2 and 5 of culture. 
All NK cells proliferated at day 2 compared to day 0 when stimulated with 
1000 IU/mL of IL-2. At day 2 the drugs did not affect the proliferation of PB or CB 
NK cells compared to untreated cells. At day 5 PB NK cells were divided into 2 
groups as they showed differences in proliferation in the presence of the drugs. 
Two out of six samples tested (group 1) showed reduced proliferation in the 
presence of the drugs. MPA- and MPA+CsA-treated NK cells showed a similar 
inhibition of proliferation compared to untreated NK cells independently of the 
dose tested, while CsA decreased NK cell proliferation in a dose dependent 
manner. In group 2, none of the drugs inhibited NK cell proliferation (Figure 10). 
Results 
 27 
In contrast, the immunosuppressive drugs inhibited NK cell proliferation of 
all CB NK cell samples. However, CsA (p<0.05) showed to be less potent than MPA 
(p<0.001) and MPA+CsA (p<0.001) (Figure 10). 
Regarding proliferation, CB NK cells showed to be more sensitive to the 
immunosuppressants than PB NK cells. 
 
Figure 10. Influence of immunosuppressants on NK cell proliferation. CFSE division 
profile at day 2 and day 5 of IL-2 (1000 IU/mL) stimulated untreated (dashed line, open 
histograms) compared to drugs-treated (heavy line, open histograms) NK cells. The CFSE 
content at day 0 is represented by a heavy line, closed histograms. As at day 5 PB NK cells 
from different individuals showed distinct profiles, they were divided in group 1 (N=2), in 
which the immunosuppressive drugs inhibited NK cell proliferation and group 2 (N=4), in 
which the immunosuppressive drugs did not inhibit NK cell proliferation. Regarding CB NK 
cells, the figure shows a set of histograms from a representative sample. NK cells from 4 
individual CB samples showed similar results. 
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4. Effects of Immunosuppressants on NK Cell Cytotoxicity 
NK cells are important effectors of the innate immune system that mediate 
cytotoxicity against infectious organisms and tumour cells without prior 
sensitisation by exocytosis of perforin and granzyme B. Perforin creates pores in 
the cell membrane of the target cell while granzyme B, a serine protease, enters 
the cell via those pores and induces apoptosis. 
To investigate the effects of immunosuppressants on NK cell killing 
machinery, NK cells were activated for 5 days with 1000 IU/mL of IL-2 and the 
drugs were added at day 5 of culture. At day 7 of culture granzyme B and perforin 
production was accessed by intracellular staining. 
It is interesting to note that CB NK cells produced far less perforin than PB 
NK cells. Furthermore, the drugs affected differentially PB and CB NK cells.  
The percentage of cells producing perforin was analysed and the perforin 
content/cell (MFI) was measured. MPA significantly decreased the percentage of 
perforin producing cells in a dose dependent manner, as well as the quantity of 
perforin produced by PB NK cells. Although CsA increased significantly the 
percentage of perforin producing cells, it did not significantly affect the global 
perforin production. Interestingly, although MPA+CsA significantly decreased the 
percentage of perforin producing PB NK cells, MPA+CsA only showed a trend to 
decrease the perforin production. In contrast, the combination of drugs seemed 
to have the opposite effect on CB NK cells, significantly increasing the percentage 
of perforin producing cells (Figure 11). 
The percentage of granzyme B producing cells, as well as the quantity of 
granzyme B produced by these cells, was very similar between PB and CB NK cells.  
The immunosuppressants did not show major effect on granzyme B 
production. Although CsA showed a trend towards the decrease of granzyme B 
production, only the highest concentration of the combination of drugs showed a 
significant decrease of granzyme B production by CB NK cells (Figure 12). 
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Figure 11. Influence of immunosuppressants on perforin expression by NK cells. 
Percentage of perforin-producing PB (N=4) and CB (N=4) NK cells (top graphs) and MFI of 
perforin produced by isolated PB (N=4) and CB (N=4) NK cells (bottom graphs) activated 
with 1000 IU/mL of IL-2 in the presence of MPA (5 and 10 µM), CsA (50 and 5000 ng/mL) 
and MPA+CsA (5 µM + 50 ng/mL and 10 µM + 5000 ng/mL). The drugs were added at day 
5 of culture and the cells were stained at day 7 of culture. *p<0.05 and **p<0.01 
compared to untreated cells. 
  
Figure 12. Influence of immunosuppressants on granzyme B expression by NK cells. 
Percentage of granzyme B-producing PB (N=4) and CB (N=4) NK cells (top graphs) and MFI 
of granzyme B produced by isolated PB (N=4) and CB (N=4) NK cells (bottom graphs) 
activated with 1000 IU/mL of IL-2 in the presence of MPA (5 and 10 µM), CsA (50 and 
5000 ng/mL) and MPA+CsA (5 µM + 50 ng/mL and 10 µM + 5000 ng/mL). The drugs were 
added at day 5 of culture and the cells were stained at day 7 of culture. *p<0.05. 
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The previous data elucidated how the immunosuppressants affect the 
intracellular content of perforin and granzyme B. However, the cells are functional 
only if they are able to degranulate following stimulation. 
Therefore, the cells were activated with 1000 IU/mL of IL-2 for five days and 
the drugs were added at day 5 of culture. At day 7 of culture cells were stained 
for CD107a after stimulation with 100 ng/mL of PMA and 1 µg/mL of ionomycin 
for 2 hours. CD107a, also known as lysosomal-associated membrane protein-1 
(LAMP-1), is a marker of degranulation for cytotoxic lymphocytes such as CD8+ T 
cells and NK cells. 
 
Figure 13. Influence of immunosuppressants on NK cell degranulation. Degranulation of 
PMA and ionomycin treated NK cells in the presence of immunosuppressive drugs. Flow 
cytometry histograms showing one representative example of CD107a surface expression 
on PB (N=3) and CB (N=4) untreated NK cells compared to MPA- (5 and 10 µM), CsA- (50 
and 5000 ng/mL) and MPA+CsA- (5 µM+50 ng/mL and 10 µM+5000 ng/mL) treated NK 
cells at day 7 of culture after 2 hours of stimulation with 100 ng/mL of PMA and 1 µg/mL 
of ionomycin. Isotype controls are shown as closed histograms. 
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Figure 13 shows one representative example of PB and CB NK cell 
degranulation in the presence or absence of the drugs. In this experiment, 
although a great variability in the amount of degranulation was observed between 
samples, all the samples showed the same degranulation profile in the presence 
of the drugs. These preliminary data showed that CsA-treated PB and CB NK cells 
exhibited a drastic reduction of degranulation compared to untreated cells. 
MPA+CsA inhibited degranulation almost totally. Surprisingly, MPA slightly 
increased PB NK cell degranulation, but slightly decreased CB NK cell 
degranulation. 
5. Relative Quantification of IMPDH1, IMPDH2 and NFATc 
Expression in PB and CB NK Cells by Quantitative Real 
Time PCR 
To understand the difference of sensitivity to the immunosuppressants 
between PB and CB NK cells, a relative quantification of the drug targets; IMPDH1, 
IMPDH2 and NFATc expression by resting and activated PB and CB NK cells was 
performed by quantitative real time PCR. 
No significant changes were observed in the expression of IMPDH1, IMPDH2 
and NFATc between PB and CB resting or activated NK cells. However, activated 
CB NK cells showed a trend towards a reduced expression of IMPDH2 and NFATc 
compared to PB NK cells (Figure 14). 
 
Figure 14. Relative expression of IMPDH1, IMPDH2 and NFATc mRNA levels 
by resting and activated NK cells. mRNA levels analysed by RT-PCR in freshly 
isolated PB (N=5) and CB (N=5) NK cells (left) and isolated PB (N=4) and CB (N=5) 
NK cells activated with IL-2 (1000 IU/mL) for 5 days (right). 
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Discussion 
CB has been increasingly used as a source of SCs for transplantation as an 
alternative to BM and mPB due to a decreased GvHD incidence, off-the-shelf 
availability and a greater tolerance to HLA disparity. NK cells reconstitute early 
after CBT, providing GvL effect, without causing GvHD. These cells have already 
proven to be beneficial for clinical outcome [65, 66]. Therefore, it is important to 
study the effects of immunosuppressive drugs on NK cells in order to select a 
prophylaxis regimen with less impact on NK cell functionality. Although the 
effects of these drugs have been well studied on T cells, their effects on PB and 
CB NK cells have been scarcely studied. MPA and CsA have been successfully used 
worldwide, alone or in combination for GvHD prophylaxis. In the present study, 
we examined if CB NK cell sensitivity to MPA and/or CsA differs from their adult 
counterparts in terms of viability, activation, proliferation and cytotoxicity. 
 
We first studied the effects of MPA and/or CsA on PB and CB NK cell viability. 
We showed that MPA significantly increase CB NK cell death. From our knowledge, 
we were the first to show that MPA induces cell death of CB NK cells in 
therapeutic and supratherapeutic doses at day 7 of culture. As MPA and the 
combination of the drugs increased cell death by 20%, this might impact on the 
post-transplant outcome, reducing the GvL effect and increasing the risk of 
infections. This data indicates that CB NK cells are more sensitive to MPA than 
their adult counterparts. In accordance with our results, a few papers have 
reported MPA as an inductor of apoptosis in lymphocytes [81-83]. Human T 
lymphocytic and monocytic cell lines treated with MPA also showed an increase in 
apoptosis [84]. On the other hand the role of CsA in inducing or inhibiting 
apoptosis is controversial [99, 102, 103, 107, 108]. This might be explained by 
experimental design differences and different cell type tested. In our 
experiments, CsA had no effects on PB or CB NK cell viability. 
 
CsA is a calcineurin inhibitor that blocks NFAT translocation into the nucleus 
and consequently the transcription of several cytokine genes such as IL-2, IL-4 
and IFN-, inhibiting cell activation. We investigated if the drugs affect NK cell 
activation by comparing the expression of CD69 and NKp44 by drug-treated NK 
cells with untreated NK cells. We found no significant difference in the expression 
of both activation markers, which is not in accordance with the results published 
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by others (Table 6). In addition to the different experimental design regarding the 
stimulus used for NK cell activation, drugs concentration and time of incubation, 
there is another major difference that must be underlined. We added the drugs to 
NK cells activated with IL-2 for 5 days, while in other studies the drugs were 
added to freshly isolated NK cells. Studies on T cell activation reported that if CsA 
was given within 1 hour after activation, it resulted in a total inhibition of T cell 
proliferation and function. On the other hand, if CsA was given more than 6 hours 
after activation there was little effect on T cell proliferation [109]. These data 
indicate that the time of drug addition is crucial, at least for CsA to prevent cell 
activation.   
Table 6. Studies reporting the effects of MPA and CsA on the expression of CD69 and 
NKp44 by NK cells. downregulation; no difference. *p<0.05 and **p<0.01. 
References Source Stimulus Days Drug Concentration 
Activation marker 
expression 
Wang et al. 
(2007) 
PB 
IL-2 (100 IU/mL) 
+ 
IL-15 (10 ng/mL) 
7 
CsA 
1000 ng/mL 
NKp44 (p=0.06) 
Lin et al. 
(2008) 
PB/CB IL-15 (10 ng/mL) 18 h CsA 1000 ng/mL 
PB 
CD69 (trend) 
CB 
 CD69* 
Eissens et al. 
(2010) 
PB 
IL-2 (100 IU/mL) 
+ 
IL-15 (10 ng/mL) 
5  
MPA 500 ng/mL 
≈ 1.56 µM 
NKp44** 
CsA 1000 ng/mL NKp44 
CsA 10-10000 ng/mL CD69 (trend) 
MPA 10-10000 ng/mL 
≈ 0.0312-31.2 µM 
CD69 (trend) 
Ohata et al. 
(2011) 
PB 
IL-2 (100 IU/mL) 
+ 
IL-15 (10 ng/mL) 
7 
MPA 10 µg/mL 
≈ 31.2 µM 
NKp44* 
 
Both Eissens et al. and Ohata et al. showed that MPA donwregulates NKp44 
on PB NK cells while we only showed a trend towards the downregulation of 
NKp44 on these cells. Moreover, the results from Wang et al. and Eissens et al. 
are not in accordance about the effects of CsA on the expression of NKp44. Wang 
et al. showed a downregulation of NKp44, while Eissens et al. showed no 
significant differences in the expression of NKp44. We showed a trend towards 
the donwregulation of NKp44 by CsA on both PB and CB NK cells. MPA+CsA 
treated cells followed the same pattern that MPA or CsA treated cells. To our 
knowledge, the effects of MPA or CsA on NKp44 expression by CB NK cells were 
not studied by other groups. Nevertheless, CB and PB NK cells showed the same 
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pattern of NKp44 expression in the presence of drugs. However, it is interesting 
to note that CB NK cells expressed more NKp44 than PB NK cells. 
None of the published studies showed a significant difference of CD69 
expression when PB NK cells were treated by either MPA or CsA, but they showed 
a trend towards the downregulation of CD69, which is in accordance with our 
results. The only study on CB NK cells showed that CsA dowregulates CD69, but 
we found no significant difference compared with the untreated cells. This might 
be explained by experimental design differences in particular by the time of drug 
addition. 
Comparing our results with what was published in the literature: we can 
conclude that there is a difference in the expression of activation markers if the 
immunosuppressive drugs are added to freshly isolated NK cells or if they are 
added to activated NK cells. Preliminary data obtained in our laboratory showed 
similar results to the literature when the drugs were added to freshly isolated NK 
cells. This might be relevant for immunotherapies of immunosuppressed patients 
using NK cell infusions, however further studies are needed.  
 
In contrast with what was published by other groups (Table 7), we showed 
minor effects of the drugs on PB NK cell proliferation. Only two out of six samples 
treated with MPA and MPA+CsA showed a reduced proliferation at day 5 of 
culture. CsA also inhibited PB NK cell proliferation in these two samples in a dose 
dependent manner. MPA and MPA+CsA inhibited more potently CB NK cell 
proliferation than CsA.  
Experimental design differences between our work and others might 
account for the contradictory results. In our study, we optimised the conditions 
for NK cell proliferation by providing close cell contact and adding fresh media 
plus IL-2 every two days, while in the other studies close cell contact was not 
provided and NK cells were cultured 5 to 9 days without refreshing the media or 
IL supply.  
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Table 7. Studies reporting the effects of MPA and CsA on NK cell proliferation by CFSE 
assay. inhibition; no difference. *p<0.05 and **p<0.01. 
References Source Stimulus Days 
Drug 
Concentration 
Proliferation 
Wang et al. 
(2007) 
PB 
IL-2 (100 IU/mL) 
+ 
IL-15 (10 ng/mL) 
3, 5, 7 and 
10 
CsA 
1000 ng/mL 
CD56+CD16- 
CD56+CD16+ 
CD56dimCD16+ * 
CD56brightCD16- * 
Eissens et al. 
(2010) 
PB 
IL-2 (100 IU/mL) 
+ 
IL-15 (10 ng/mL) 
5  
MPA 
100-10000 ng/mL 
≈ 0.312-31.2 µM 
*** 
CsA 
100-10000 ng/mL 
(trend)
Ohata et al. 
(2011) 
PB 
IL-2 (100 IU/mL) 
+ 
IL-15 (10 ng/mL) 
1, 5 and 9 
CsA 
1000 ng/mL 

MPA 
1-100 µg/mL 
≈ 0.312-31.2 µM 

 
Several studies reported controversial results regarding the effects of CsA 
on NK cell cytotoxicity. Eissens et al. and Ohata et al. recently reported that CsA 
did not impair IL-2 and IL-15 activated PB NK cell cytotoxicity against K562 cells 
[85, 86]. Ohata et al. also studied the effects of CsA on PB NK cell cytotoxicity 
against Daudi cells, showing a trend towards an increased cytotoxicity [85]. 
Moreover, Wang et al. reported that CsA improved cytolytic activity of IL-2 and IL-
15 activated PB NK cells against K562 and Raji cells [96]. However, Lin et al. 
published that CsA did not affect K562 cytolysis by unstimulated CB and PB NK 
cells, but did significantly suppress K562 cytolysis by IL-15 activated CB and PB 
NK cells [97]. 
To our knowledge, there are few studies reporting the effects of MPA on NK 
cell cytotoxicity, but the existing data show that MPA impairs cytolytic activity of 
PB NK cells [85, 86]. 
Our study regarding the effects of MPA and/or CsA on NK cell cytotoxicity is 
based on the analysis of perforin and granzyme B intracellular production and in 
the capacity of NK cells to degranulate after activation. We showed that MPA 
significantly decreased perforin production by PB NK cells, but not by CB NK cells. 
These data could explain the impaired cytotoxicity of MPA-treated PB NK cells 
against K562 and Daudi cells published by other groups [85, 86]. CsA did not 
affect perforin levels in PB NK cells, which is in accordance with results published 
by Wang et al. [96]. In contrast, CsA significantly increased the percentage of 
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perforin producing CB NK cells and induced a trend towards the increase of 
global perforin production. Lin et al. reported that CsA did not affect intracellular 
perforin production of IL-15 activated CB NK cells [97].   
Importantly, CsA drastically inhibited both PB and CB NK cell degranulation, 
shown by a significant decrease in CD107a expression, which might explain the 
impaired cytotoxicity of CsA-treated CB NK cells reported by Lin et al. [97]. 
However, this result is not in accordance with the observations made by Eissens 
et al., Ohata et al. and Wang et al. Despite the controversy in the results reported 
in these papers regarding the effects of CsA on NK cell cytotoxicity, none of them 
reported an impairment of PB NK cell cytotoxicity. On the other hand, several 
papers reported a blocking by CsA of Ca
2+
 dependent degranulation in a mast cell 
line, basophils and cytolytic T lymphocytes by CsA [93-95]. MPA+CsA showed a 
trend to reduce perforin production by PB NK cells, but showed a trend to 
increase perforin production by CB NK cells. Most importantly, MPA+CsA inhibited 
almost completely the degranulation of PB and CB NK cells suggesting an 
impairment of perforin and granzyme B release. It is interesting to note that 
despite the stimulation of CB NK cells with 1000 IU/mL of IL-2 perforin levels 
were much lower than in PB NK cells, although several papers have published that 
IL-2 enhances CBMCs cytotoxicity [110-112]. IL-2 activated CBMCs were shown to 
have a higher cytolytic activity than IL-2 activated PBMCs depending on the 
targets [110]. Moreover, Joshi et al. suggested that the increase of CBMCs 
cytotoxicity after IL-2 activation was mediated by FasL and by perforin/granzyme-
mediated target cell lysis [110]. 
PB and CB NK cells expressed similar levels of granzyme B and, in general, 
the drugs did not seem to affect its expression. Only the highest concentration of 
MPA+CsA, a supratherapeutic dose, significantly decreased granzyme B 
production by CB NK cells. 
We should bear in mind that perforin/granzyme B mediated lysis is not the 
only mechanism by which NK cells kill their targets. Other mechanisms, such as 
FasL mediated cytotoxicity and ADCC, are also used by NK cells against tumour 
cells and infectious organisms.  
These data should be complemented with an in vitro cytotoxic assay against 
K562 cells to clarify what are the effects of the drugs on NK cell cytotoxicity 
against a haematopoietic malignant cell line and to confirm whether PB and CB 
NK cells are capable of comparable cytotoxicity. 
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Nevertheless, our data suggest that MPA, CsA and MPA+CsA could 
jeopardise NK cell cytotoxicity.  
Regarding the effect of MPA on NK cell cytotoxicity, we would expect a 
higher sensitivity of PB NK cells compared to CB NK cells, as besides 
degranulation, MPA also decreased perforin production by PB NK cells, but not by 
CB NK cells.  
   
In general, CB NK cells seemed to be more sensitive to the 
immunosuppressants than PB NK cells. Thus, we hypothesised that this difference 
could be explained by a lower expression of the known drug targets on CB NK 
cells compared to PB NK cells. However, the analysis of IMPDH1, IMPDH2 and 
NFATc expression by resting and activated PB and CB NK cells by quantitative real 
time PCR did not reveal significant difference of drug target expression between 
PB and CB NK cells. Therefore, we could not conclude on the mechanism 
underlying the higher sensitivity of CB NK cells. However, we should not exclude 
the hypothesis that the drugs could affect other molecular targets. To our 
knowledge, the quantification of drug targets in PB and CB NK cells has not been 
reported yet. 
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Conclusion 
This work intended to compare the effects of MPA and/or CsA on PB and CB 
NK cells in order to provide a better understanding of the sensitivity to the drugs 
of NK cells from different sources.   
All drugs tested showed significant effects on NK cells that could jeopardise 
their beneficial effect as prophylaxis after HSCT. Surprisingly, MPA was the only 
drug that seemed to preserve CB NK cell cytotoxicity via perforin/granzyme B 
secretion compared to untreated CB NK cells, however, CB NK cells seemed to be 
less cytotoxic than PB NK cells even after IL-2 stimulation. Another important 
effect observed was the increase of cell death caused by MPA and MPA+CsA on CB 
NK cells. We also showed that the drugs inhibited more efficiently CB NK cell 
proliferation than PB NK cell proliferation. 
We demonstrated that CB NK cells are more sensitive to the drugs than PB 
NK cells since the same dosage showed a less severe effect or no effect at all on 
PB NK cells. These data suggest that, if confirmed by in vivo studies, the 
immunosuppressive drugs dosage could be adjusted for CBT or maybe 
alternatives to MMF and CsA could be considered in order to prevent GvHD and 
preserve NK cell functionality. 
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Future Perspectives 
This study was part of a project aimed to study the effects of MMF and/or 
CsA on PB and CB immune cells, stem cell engraftment and immune 
reconstitution in vitro.  
Regarding the in vitro effects of the immunosuppressive drugs on NK cells, 
it is crucial to test the cytotoxicity of the drug-treated NK cells against cancer cell 
lines. The most common cell line used to measure NK cell activity is K562, which 
is a human chronic myeloid leukemic cell line that does not express MHC class I 
molecules. Furthermore, it would be interesting to study the effects of the drugs 
on cytokine production, as CsA impairs cytokine production. Some cytokines 
produced by NK cells, such as IFN- and TNF were shown to play a role in the GvL 
effect mediated by NK cells [113, 114]. In vivo data are needed to support and 
complement the in vitro data. The most important in vivo experiment should 
answer whether the immunosuppressants decrease GvL effect or increase the risk 
of infections.  
This project will provide a better understanding of the effects of the 
immunosuppressive drugs on PB and CB immune cells and SCs, and should help 
to identify the best immunosuppressive regimen as well as the dosage to control 
GvHD while preserving GvL effect and thus improve the outcome of patients after 
transplantation.
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